Treatment with xalnesiran, a small interfering RNA molecule, plus an immunomodulator resulted in hepatitis B surface antigen loss among adults with chronic HBV infection, according to a study ...

Researchers update clinical practice guidelines for how to prevent and monitor hepatitis B virus reactivation.

The FDA has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta.

T lymphocytes play a pivotal role in resolving hepatitis B virus infection. This study aimed to investigate the dynamics of peripheral blood T ...

At 72 weeks, IHCs in the treatment group were categorized into an HBsAg clearance group and an HBsAg persistence group. Differences in T lymphocyte subsets among these groups were compared ...

Breakthrough Therapy Designation is designed to expedite the development and review of therapies that may show significant ...

Treatment with xalnesiran, a small interfering RNA molecule, plus an immunomodulator resulted in hepatitis B surface antigen loss among adults with chronic HBV infection, according to a study ...

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Bluejay Therapeutics’ fully human ...

A functional cure is said to have been achieved if HBsAg is cleared from the blood and remains undetectable after stopping all treatment. In B-Clear, patients with low baseline HBsAg levels ...

US FDA grants breakthrough therapy designation to Bluejay Therapeutics’ brelovitug for treatment of chronic hepatitis delta: Redwood City, California Thursday, January 23, 2025, ...

Assays for hepatitis B surface antigen (HBsAg) are the most frequently used tests to detect HBV infection. Vaccination for HBV can produce transiently detectable levels of HBsAg in patients.